June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Sustained Intravitreal Delivery of Small and Large Molecules with Injectable Hydrogels
Author Affiliations & Notes
  • Mark Tibbitt
    Koch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Andrew Auerbach
    Koch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Ashwath Jayagopal
    Pharma Research and Early Development, Ophthalmology Discovery and Biomarkers, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd, Basel, Switzerland
  • Robert Langer
    Koch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Mark Tibbitt, None; Andrew Auerbach, None; Ashwath Jayagopal, F. Hoffmann-La Roche Ltd (E); Robert Langer, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2971. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mark Tibbitt, Andrew Auerbach, Ashwath Jayagopal, Robert Langer; Sustained Intravitreal Delivery of Small and Large Molecules with Injectable Hydrogels. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2971.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Approaches for the controlled release of therapeutics inhibiting neovascularization are needed to improve the clinical management of age-related macular degeneration (AMD). Currently, AMD is managed by monthly intravitreal injections of solutions of anti-angiogenesis biotherapeutics, creating a significant burden on both patient and clinician. The goal of this study was to develop a new platform for sustained release of small molecule drugs and biotherapeutics over the course of 6 months following intravitreal injection for the treatment of AMD.

Methods : Polymer-nanoparticle (PNP) hydrogels were engineered for facile intravitreal injection through narrow gauge needles owing to the high-degree of shear-thinning observed in these materials. The PNP gels were designed to form a drug delivery depot in the vitreous on account of the rapid self-healing following injection. Small molecule drugs were encapsulated into the nanoparticles using nanoprecipitation prior to PNP hydrogel fabrication. Additionally, biotherapeutics (e.g., model IgG and Fab antibodies) were entrapped within the aqueous phase of the PNP hydrogels upon gel fabrication. The PNP hydrogels were engineered to release both classes of drugs over the course of 6 months, with independently tunable release rates. Drug loading and release was measured in vitro and in vivo with HPLC, electro-retinography, and confocal imaging of tissue sections. PNP hydrogel stability, ocular tolerability via histopathology, toxicity, and drug release were evaluated in tissue culture and animal models (rat and rabbit).

Results : PNP gels comprised an intravitreal drug delivery depot following administration through narrow gauge needles allowing for tunable sustained delivery of both small molecules and biotherapeutics in vitro and in vivo. Moreover, the delivery depots demonstrated in vivo tolerability as assessed by histopathology.

Conclusions : Drug-loaded PNP hydrogels provide a promising platform for the management of AMD via intravitreal depots that sustain release for months to a year. On account of their biocompatibility and controlled release of therapeutics, PNP hydrogels can be used for mitigating the burden of monthly intravitreal injections in the management of AMD, improving adherence and clinical outcome.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×